Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

In this randomized, observer-blinded, phase 2/3 study, S-268019-b (n = 101), a recombinant spike protein vaccine, was analyzed for noninferiority versus BNT162b2 (n = 103), when given as a booster ≥6 months after 2-dose BNT162b2 regimen in Japanese adults without prior SARS-CoV-2 infection. Interim...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinkai, Masaharu, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Yokokawa, Seki, Naomi M., Omoto, Shinya, Shinoda, Masahiro, Sato, Takashi, Ishii, Naoki, Igarashi, Kenji, Ariyasu, Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212435/
https://www.ncbi.nlm.nih.gov/pubmed/35738968
http://dx.doi.org/10.1016/j.vaccine.2022.06.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212435/
https://www.ncbi.nlm.nih.gov/pubmed/35738968
http://dx.doi.org/10.1016/j.vaccine.2022.06.032

Ejemplares similares